Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
to TREMFYA litigation (Ligand would receive 25% of any net proceeds after legal costs), with the deal expected to close in Q3 2026 and be "immediately accretive" to earnings. The transaction will more than double Ligand's royalty portfolio—adding seven commercial royalties and over 100 partnered development-stage programs—with near-term catalysts including VABYSMO, OJEMDA and osavampator. Ligand raised its 2026 guidance to royalty revenue of $225M–$250M , total revenue of $270M–$310M and adjusted EPS of $8.50–$9.50, and expects the acquisition to add about $0.50 to adjusted EPS in 2026 (assuming a Q3 close) and $1.50 in 2027. Interested in Ligand Pharmaceuticals Incorporated? Here are five stocks we like better. Ligand Pharmaceuticals (NASDAQ:LGND) detailed plans to acquire XOMA Royalty Corporation in an investor call, outlining what executives described as a “highly complementary” transaction intended to expand Ligand's royalty portfolio and accelerate growth. Under the defin
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty CorporationPR Newswire
- Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript [Seeking Alpha]Seeking Alpha
- Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator GlobeNewswire
- Ligand to Report First Quarter 2026 Financial Results on May 7, 2026GlobeNewswire
- Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a "buy" rating on the stock.MarketBeat
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 4/27/26 - Form DEFA14A
- 4/27/26 - Form 8-K
- 4/21/26 - Form ARS
- LGND's page on the SEC website